Hemostats - Medical Devices Pipeline Assessment, 2018

Hemostats - Medical Devices Pipeline Assessment, 2018

Summary

Medical Devices sector report, Hemostats - Medical Devices Pipeline Assessment, 2018" provides an overview of Hemostats currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hemostats pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Hemostats under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Hemostats and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry.

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Hemostats under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date.


1.1 List of Tables 8
1.2 List of Figures 12
2 Introduction 13
2.1 Hemostats Overview 13
3 Products under Development 14
3.1 Hemostats - Pipeline Products by Stage of Development 14
3.2 Hemostats - Pipeline Products by Segment 15
3.3 Hemostats - Pipeline Products by Territory 16
3.4 Hemostats - Pipeline Products by Regulatory Path 17
3.5 Hemostats - Pipeline Products by Estimated Approval Date 18
3.6 Hemostats - Ongoing Clinical Trials 19
4 Hemostats - Pipeline Products under Development by Companies 20
4.1 Hemostats Companies - Pipeline Products by Stage of Development 20
4.2 Hemostats - Pipeline Products by Stage of Development 22
5 Hemostats Companies and Product Overview 24
5.1 3-D Matrix Ltd Company Overview 24
5.1.1 3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview 24
5.2 Angiotech Pharmaceuticals Inc Company Overview 28
5.2.1 Angiotech Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 28
5.3 Anika Therapeutics Inc Company Overview 29
5.3.1 Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 29
5.4 APRUS Bio-Medical Innovations Pvt Ltd Company Overview 30
5.4.1 APRUS Bio-Medical Innovations Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 30
5.5 Arch Therapeutics Inc Company Overview 31
5.5.1 Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 31
5.6 Baxter International Inc Company Overview 33
5.6.1 Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview 33
5.7 Beth Israel Deaconess Medical Center Inc Company Overview 39
5.7.1 Beth Israel Deaconess Medical Center Inc Pipeline Products & Ongoing Clinical Trials Overview 39
5.8 Biomedica Management Corp Company Overview 40
5.8.1 Biomedica Management Corp Pipeline Products & Ongoing Clinical Trials Overview 40
5.9 BiomUp SAS Company Overview 43
5.9.1 BiomUp SAS Pipeline Products & Ongoing Clinical Trials Overview 43
5.10 C. R. Bard Inc Company Overview 47
5.10.1 C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 47
5.11 Cellphire Inc Company Overview 49
5.11.1 Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview 49
5.12 Ceramicos Para Aplicacoes Medicas SA Company Overview 51
5.12.1 Ceramicos Para Aplicacoes Medicas SA Pipeline Products & Ongoing Clinical Trials Overview 51
5.13 Columbia University Company Overview 52
5.13.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 52
5.14 Covalent Medical, Inc. (Inactive) Company Overview 53
5.14.1 Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 53
5.15 Covalon Technologies Ltd Company Overview 54
5.15.1 Covalon Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 54
5.16 Cresilon Inc Company Overview 56
5.16.1 Cresilon Inc Pipeline Products & Ongoing Clinical Trials Overview 56
5.17 CryoLife Inc Company Overview 58
5.17.1 CryoLife Inc Pipeline Products & Ongoing Clinical Trials Overview 58
5.18 Endomedix Incorporated Company Overview 61
5.18.1 Endomedix Incorporated Pipeline Products & Ongoing Clinical Trials Overview 61
5.19 Entegrion Inc Company Overview 63
5.19.1 Entegrion Inc Pipeline Products & Ongoing Clinical Trials Overview 63
5.20 Ethicon US LLC Company Overview 64
5.20.1 Ethicon US LLC Pipeline Products & Ongoing Clinical Trials Overview 64
5.21 ETX Pharma Inc Company Overview 67
5.21.1 ETX Pharma Inc Pipeline Products & Ongoing Clinical Trials Overview 67
5.22 Gamma Therapeutics Inc Company Overview 68
5.22.1 Gamma Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 68
5.23 GATT Technologies BV Company Overview 69
5.23.1 GATT Technologies BV Pipeline Products & Ongoing Clinical Trials Overview 69
5.24 gel-e Inc Company Overview 71
5.24.1 gel-e Inc Pipeline Products & Ongoing Clinical Trials Overview 71
5.25 Haemostatix Ltd Company Overview 73
5.25.1 Haemostatix Ltd Pipeline Products & Ongoing Clinical Trials Overview 73
5.26 Hemostasis LLC Company Overview 75
5.26.1 Hemostasis LLC Pipeline Products & Ongoing Clinical Trials Overview 75
5.27 KeraNetics, LLC Company Overview 77
5.27.1 KeraNetics, LLC Pipeline Products & Ongoing Clinical Trials Overview 77
5.28 Leader Biomedical Europe BV Company Overview 78
5.28.1 Leader Biomedical Europe BV Pipeline Products & Ongoing Clinical Trials Overview 78
5.29 LifeBond Ltd Company Overview 79
5.29.1 LifeBond Ltd Pipeline Products & Ongoing Clinical Trials Overview 79
5.30 Resorba GmbH Company Overview 80
5.30.1 Resorba GmbH Pipeline Products & Ongoing Clinical Trials Overview 80
5.31 Rice University Company Overview 82
5.31.1 Rice University Pipeline Products & Ongoing Clinical Trials Overview 82
5.32 Sanofi Company Overview 83
5.32.1 Sanofi Pipeline Products & Ongoing Clinical Trials Overview 83
5.33 Sea Run Holdings Inc Company Overview 85
5.33.1 Sea Run Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 85
5.34 St Teresa Medical Inc Company Overview 86
5.34.1 St Teresa Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 86
5.35 The Medicines Company Overview 88
5.35.1 The Medicines Company Pipeline Products & Ongoing Clinical Trials Overview 88
5.36 Therus Corporation Company Overview 89
5.36.1 Therus Corporation Pipeline Products & Ongoing Clinical Trials Overview 89
5.37 Thrombotargets Corp Company Overview 90
5.37.1 Thrombotargets Corp Pipeline Products & Ongoing Clinical Trials Overview 90
5.38 United Health Products, Inc. Company Overview 92
5.38.1 United Health Products, Inc. Pipeline Products & Ongoing Clinical Trials Overview 92
5.39 University of Grenoble Alpes Company Overview 94
5.39.1 University of Grenoble Alpes Pipeline Products & Ongoing Clinical Trials Overview 94
5.40 Virginia Commonwealth University Company Overview 95
5.40.1 Virginia Commonwealth University Pipeline Products & Ongoing Clinical Trials Overview 95
5.41 WNDM Medical Inc Company Overview 96
5.41.1 WNDM Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 96
5.42 Xcede Technologies Inc Company Overview 97
5.42.1 Xcede Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 97
6 Hemostats- Recent Developments 102
6.1 Jun 06, 2018: Advanced Medical Solutions announces retirement of CFO 102
6.2 Jun 05, 2018: Johnson & Johnson Announces Progress Toward Health for Humanity Goals 102
6.3 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value 103
6.4 May 31, 2018: Merit Medical Announces Leadership Change and Appointment of Interim CFO 104
6.5 May 28, 2018: Beactica Signs Three-Year Extension Agreement With Sanofi 104
6.6 May 28, 2018: Covalon Announces Major Corporate Initiatives and Second Quarter Results 104
6.7 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results 105
6.8 May 21, 2018: Baxter Highlights Business Strategies and Innovation at 2018 Investor Conference 108
6.9 May 10, 2018: Partnership Agreement concluded with DEMEDIC regarding sales and marketing of absorbable local hemostat PuraStat in Argentina 110
6.10 May 09, 2018: Sanofi lays off 95 workers in Framingham 110
6.11 May 08, 2018: Arch Therapeutics Provides Update on Study Initiation and 510(k) 110
6.12 May 08, 2018: Arch Therapeutics Provides Update on Study Initiation and 510(k) 111
6.13 May 08, 2018: Sanofi Announces Appointment of Mr. Charles Billard as Chief Financial Officer and Key Managerial Personnel 111
6.14 May 07, 2018: FDA permits marketing of new endoscopic device for treating gastrointestinal bleeding 112
6.15 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy 112
6.16 May 07, 2018: Covalon Announces Major Sales Breakthrough - Wins Contracts with an Estimated Value of $100 Million Over a Three-Year Period 113
6.17 May 02, 2018: Biomup Finalizes U.S. Commercial Organization to Support U.S. Launch of HEMOBLAST Bellows 114
6.18 May 02, 2018: CryoLife Announces First Quarter 2018 Financial Results 114
6.19 May 02, 2018: Anika Reports First Quarter 2018 Financial Results 116
6.20 May 01, 2018: United Health Products Expands Animal Testing for HemoStyp in Support of PMA Application, Human Trials to Follow 117
6.21 Apr 27, 2018: Sanofi: First-quarter 2018 Business EPS up 1.4% at CER 117
6.22 Apr 26, 2018: Baxter Reports First-Quarter 2018 Results And Increases Financial Outlook For Full-Year 2018 125
6.23 Apr 26, 2018: Stryker reports first quarter 2018 operating results 127
6.24 Apr 25, 2018: The Medicines Company Reports First-Quarter 2018 Results 127
6.25 Apr 25, 2018: Merit Medical Reports First Quarter of 2018 Financial Results 129
6.26 Apr 24, 2018: Biomup Has Trained 200 Surgeons in its International KOL-Led Program Ahead of HEMOBLAST Bellows Launch 130
6.27 Apr 24, 2018: Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1 130
6.28 Apr 20, 2018: Cook Medical Appoints Christina Anne Vice President of Distribution Channel Management 131
6.29 Apr 17, 2018: Johnson & Johnson Reports 2018 First-Quarter Results 132
6.30 Apr 16, 2018: Biomup reports 2017 full-year results and provides corporate update 134
6.31 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics 135
6.32 Apr 03, 2018: Wound Management Technologies Changes Name to WNDM Medical 136
6.33 Mar 29, 2018: Wound Management Technologies Announces Record Annual Sales Ending December 31, 2017 - Up 14% over 2016 137
6.34 Mar 28, 2018: Sanofi: Pre - quarterly Results Communication 137
6.35 Mar 27, 2018: The Medicines Company Announces Chief Financial Officer Transition 139
6.36 Mar 23, 2018: 2017 fiscal year: B. Braun increases sales and earnings, with investments of one billion euros 139
6.37 Mar 20, 2018: LiDCO Group: End of third party UK Distribution agreement 142
6.38 Mar 20, 2018: Dominic J. Caruso to Retire as Chief Financial Officer of Johnson & Johnson 142
6.39 Mar 19, 2018: United Health Products Forms Medical Advisory Board 143
6.40 Mar 14, 2018: Advanced Medical Solutions Group: Unaudited Preliminary Results for the year ended 31 December 2017 144
6.41 Mar 13, 2018: United Health Products Receives CE Mark Approval for HemoStyp 151
6.42 Mar 12, 2018: Arch Therapeutics Provides Update on 510(k) 151
6.43 Mar 12, 2018: Arch Therapeutics Provides Update on 510(k) 152
6.44 Mar 07, 2018: CryoLife Reports Fourth Quarter and Full Year 2017 Results 153
6.45 Mar 06, 2018: Sanofis Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director 154
6.46 Mar 05, 2018: Anika Therapeutics Names Joseph Darling As CEO And Director 154
6.47 Feb 28, 2018: Axiostat Chitosan Hemostatic Dressing gets USFDA approval 155
6.48 Feb 28, 2018: Merit Medical Reports Results for Fourth Quarter and Year Ended December 31, 2017; Merit Meets Range of 2017 Guidance; Gives 2018 Guidance 156
6.49 Feb 27, 2018: The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors 157
6.50 Feb 27, 2018: Z-Medica Announces Appointment Of Eric Compton As CEO 157
6.51 Feb 21, 2018: The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results 158
6.52 Feb 21, 2018: Anika Announces Fourth Quarter and Full Year 2017 Financial Results 159
6.53 Feb 15, 2018: Wound Management Technologies Announces J. Michael Carmena Appointed Chief Executive Officer 161
6.54 Feb 13, 2018: Four start-ups chosen for the B. Braun Accelerator Program 161
6.55 Feb 12, 2018: Covalon Announces Strong First Quarter Financial Results 2017 162
6.56 Feb 07, 2018: Sanofi Delivers 2017 Business EPS in line with Guidance 163
6.57 Feb 05, 2018: United Health Products Announces Completion Of FDA PMA For HemoStyp 165
6.58 Feb 01, 2018: Baxter Reports 2017 Fourth-Quarter and Full-Year Results 165
6.59 Jan 30, 2018: United Health Products Issues Update on HemoStyp South Korea MFDS Application 168
6.60 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronics Greater China Region 168
6.61 Jan 30, 2018: Stryker reports 2017 results and 2018 outlook 169
6.62 Jan 25, 2018: Lohmann & Rauscher: Personnel Change in Executive Board of L&R 170
6.63 Jan 23, 2018: Johnson & Johnson Reports 2017 Fourth-Quarter Results 171
6.64 Jan 22, 2018: United Health Products Provides FDA Update 173
6.65 Jan 19, 2018: Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee 173
6.66 Jan 11, 2018: Xcede Hemostatic Patch Clinical Trial Dossier Submitted to Groningen-based Medical Ethical Review Committee (MREC) in Anticipation of First-in-Human Clinical Trial 174
6.67 Jan 09, 2018: New Absorbable Adjunctive Hemostat from Ethicon Helps Surgeons Control Disruptive Bleeding more Efficiently 174
6.68 Jan 09, 2018: United Health Products Gains Patent Protection Extension for HemoStyp 175
6.69 Jan 09, 2018: Stryker provides 2017 preliminary net sales results 175
6.70 Jan 08, 2018: Z-Medica Officially Launches QuikClot Control+ 176
7 Appendix 252
7.1 Methodology 252
7.2 About GlobalData 255
7.3 Contact Us 255
7.4 Disclaimer 255

List Of Tables

1.1 List of Tables
Table 1: Hemostats - Pipeline Products by Stage of Development 14
Table 2: Hemostats - Pipeline Products by Segment 15
Table 3: Hemostats - Pipeline Products by Territory 16
Table 4: Hemostats - Pipeline Products by Regulatory Path 17
Table 5: Hemostats - Pipeline Products by Estimated Approval Date 18
Table 6: Hemostats - Ongoing Clinical Trials 19
Table 7: Hemostats Companies - Pipeline Products by Stage of Development 20
Table 8: Hemostats - Pipeline Products by Stage of Development 22
Table 9: 3-D Matrix Ltd Pipeline Products & Ongoing Clinical Trials Overview 24
Table 10: PuraStat Hemostat - Product Status 24
Table 11: PuraStat Hemostat - Product Description 25
Table 12: TDM-511 - Product Status 25
Table 13: TDM-511 - Product Description 25
Table 14: 3-D Matrix Ltd - Ongoing Clinical Trials Overview 26
Table 15: PuraStat Hemostat - A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat Absorbable Haemostatic Material for the Management of Bleeding in Vascular Surgery 27
Table 16: PuraStat Hemostat - Randomized Controlled Trial Comparing Purastat to Standard Therapy for Haemostasis Control During Endoscopic Submucosal Dissection 27
Table 17: Angiotech Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 28
Table 18: Hemaseel Thrombin Haemostatic Agent - Product Status 28
Table 19: Hemaseel Thrombin Haemostatic Agent - Product Description 28
Table 20: Anika Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 29
Table 21: Hemostatic Patch - Product Status 29
Table 22: Hemostatic Patch - Product Description 29
Table 23: APRUS Bio-Medical Innovations Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 30
Table 24: Deep Wound Hemostat - Product Status 30
Table 25: Deep Wound Hemostat - Product Description 30
Table 26: Arch Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 31
Table 27: AC5 Surgical Hemostatic Device - Product Status 31
Table 28: AC5 Surgical Hemostatic Device - Product Description 31
Table 29: AC5 Surgical Hemostatic Device - Internal Use - Product Status 32
Table 30: AC5 Surgical Hemostatic Device - Internal Use - Product Description 32
Table 31: AC5 Topical Gel - Product Status 32
Table 32: AC5 Topical Gel - Product Description 32
Table 33: Baxter International Inc Pipeline Products & Ongoing Clinical Trials Overview 33
Table 34: Hemopatch - Product Status 33
Table 35: Hemopatch - Product Description 33
Table 36: Baxter International Inc - Ongoing Clinical Trials Overview 34
Table 37: Hemopatch - A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures on High Risk Population for Prolonged Air Leak (more than 5 Days - PAL) 35
Table 38: Hemopatch - A Prospective Randomized Trial of Hemopatch Versus No Hemopatch for the Intraoperative Hemostasis During Deceased Donor Renal Transplant 35
Table 39: Hemopatch - A Randomized, Controlled, Non-inferiority Study to Evaluate the Efficacy and Safety of Hemopatch Compared to TachoSil in Preventing or Reducing Postoperative Air Leaks After Pulmonary Resection 35
Table 40: Hemopatch - A Single-arm Phase II Trial of Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy 36
Table 41: Hemopatch - Assessment of the Usefulness of Hemopatch in Coronary Artery Bypass Graft Surgery 36
Table 42: Hemopatch - Exploratory Phase IV Randomized Single Blind Study Evaluating the Efficacy and Tolerability of Hemopatch in Improving Time of Hemostasis and Preventing Post-operative Complications After Hepatic Resection 36
Table 43: Hemopatch - Hemopatch Performance Evaluation: A Prospective Observational Registry 37
Table 44: Hemopatch - Phase III, Randomized, Unblinded, Controlled Clinical Trial for Evaluating the Effectiveness of the use of the New Hemostatic Patch Hemopatch in Patients undergoing Surgical Liver Resection 37
Table 45: Hemopatch - Prospective Randomized Clinical Trial to Prevent Air Leaks After Lung Resection with Hemopatch Sealing Hemostat: SEALLS (Sealing Evaluation of Air Leaks After Lung Surgery) Trial 37
Table 46: Hemopatch - Prospective, Multicenter, Open-label, Randomized, Phase III Clinical Trial of Prevention of Prolonged Air Leak after Lung Resection in High-risk Patients, Applying HEMOPATCH 38
Table 47: Beth Israel Deaconess Medical Center Inc Pipeline Products & Ongoing Clinical Trials Overview 39
Table 48: Portable Wound Hemostasis System - Product Status 39
Table 49: Portable Wound Hemostasis System - Product Description 39
Table 50: Biomedica Management Corp Pipeline Products & Ongoing Clinical Trials Overview 40
Table 51: ClotFoam - Product Status 40
Table 52: ClotFoam - Product Description 40
Table 53: ClotGel - Product Status 41
Table 54: ClotGel - Product Description 41
Table 55: ClotSpray - Product Status 41
Table 56: ClotSpray - Product Description 42
Table 57: BiomUp SAS Pipeline Products & Ongoing Clinical Trials Overview 43
Table 58: Hemoblast Bellows - Product Status 43
Table 59: Hemoblast Bellows - Product Description 43
Table 60: HEMOSNOW - Product Status 44
Table 61: HEMOSNOW - Product Description 44
Table 62: BiomUp SAS - Ongoing Clinical Trials Overview 45
Table 63: Hemoblast Bellows - Prospective, Randomized, Controlled, Multicenter, Pivotal, Clinical Investigation Evaluating the Safety and Efficacy of Hemoblast Bellows in Cardiothoracic, Abdominal, and Orthopedic Lower Extremity Surgeries 46
Table 64: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview 47
Table 65: New Hemostat 1 - Product Status 47
Table 66: New Hemostat 1 - Product Description 47
Table 67: New Hemostat 2 - Product Status 48
Table 68: New Hemostat 2 - Product Description 48
Table 69: Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview 49
Table 70: Thromboderm - Product Status 49
Table 71: Thromboderm - Product Description 49
Table 72: Thrombosomes - Product Status 50
Table 73: Thrombosomes - Product Description 50
Table 74: Ceramicos Para Aplicacoes Medicas SA Pipeline Products & Ongoing Clinical Trials Overview 51
Table 75: HemoKi - Product Status 51
Table 76: HemoKi - Product Description 51
Table 77: Columbia University Pipeline Products & Ongoing Clinical Trials Overview 52
Table 78: Hemostatic Wound Dressing - Product Status 52
Table 79: Hemostatic Wound Dressing - Product Description 52
Table 80: Covalent Medical, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 53
Table 81: CovaSTAT - Product Status 53
Table 82: CovaSTAT - Product Description 53
Table 83: Covalon Technologies Ltd Pipeline Products & Ongoing Clinical Trials Overview 54
Table 84: ColActive THP - Product Status 54
Table 85: ColActive THP - Product Description 54
Table 86: CovaStat BioActive Absorbable Hemostatic Sponge - Product Status 55
Table 87: CovaStat BioActive Absorbable Hemostatic Sponge - Product Description 55
Table 88: Cresilon Inc Pipeline Products & Ongoing Clinical Trials Overview 56
Table 89: TRAUMAGEL - Product Status 56
Table 90: TRAUMAGEL - Product Description 56
Table 91: VETIGEL - Product Status 57
Table 92: VETIGEL - Product Description 57

List Of Figures

1.2 List of Figures
Figure 1: Hemostats - Pipeline Products by Stage of Development 14
Figure 2: Hemostats - Pipeline Products by Segment 15
Figure 3: Hemostats - Pipeline Products by Territory 16
Figure 4: Hemostats - Pipeline Products by Regulatory Path 17
Figure 5: Hemostats - Pipeline Products by Estimated Approval Date 18
Figure 6: Hemostats - Ongoing Clinical Trials 19

Hemostats - Medical Devices Pipeline Assessment, 2018

Hemostats - Medical Devices Pipeline Assessment, 2018Medical Devices sector report, Hemostats - Medical Devices Pipeline Assessment, 2018 provides an overview of Hemostats currently in pipeline stage.The report provides comprehensive information

USD 4000 View Report

Global Hemostats For Wound Closure Industry Market Research Report

Based on the Hemostats For Wound Closure industrial chain, this report mainly elaborate the definition, types, applications and major players of Hemostats For Wound Closure market in details. Deep analysis

USD 2960 View Report

Micropos Medical AB (MPOS) - Medical Equipment - Deals and Alliances Profile

Micropos Medical AB (Micropos Medical) is a medical device company. The company develops technologies that enhance the precision in radiotherapy of cancer including hypofractionation and stereotactic radio surgery (SRS) and

USD 250 View Report

ANGLE Plc (AGL) - Medical Equipment - Deals and Alliances Profile

ANGLE Plc (ANGLE) is a medical diagnostic company that offers cancer diagnostics and foetal health products. The company develops products for use in rare cell diagnostics that enable early, accurate

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available